Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition.
On March6, 2017, Recro Pharma, Inc. (the Company) issued a
press release announcing its financial results for the fourth
quarter and full year ended December31, 2016. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K.
The information in the second paragraph of Item 8.01 below
regarding certain financial slides in the Companys updated slide
presentation and slides 35 and 38 of the presentation attached
hereto as Exhibit 99.2, are incorporated into this Item 2.02 by
reference.
The information disclosed under Item 2.02, including Exhibit
99.1, is being furnished and shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, and shall not be deemed to be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item8.01 Other Events.
On March6, 2017, the Company updated information reflected in a
slide presentation, including certain financial information,
which is attached as Exhibit 99.2 to this Current Report on Form
8-K and is incorporated herein by reference. Representatives of
the Company will use the updated presentation in various meeting
with investors from time to time.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Document |
|
| 99.1 | Press release of Recro Pharma, Inc., dated March6, 2017. | |
| 99.2 | Investor presentation of Recro Pharma, Inc. |
About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients. Recro Pharma, Inc. (NASDAQ:REPH) Recent Trading Information
Recro Pharma, Inc. (NASDAQ:REPH) closed its last trading session down -0.03 at 7.60 with 85,895 shares trading hands.
